HZNP - Horizon Therapeutics Non-GAAP EPS of $1.21 beats by $0.12 revenue of $942M beats by $19.05M
- Horizon Therapeutics press release ( NASDAQ: HZNP ): Q4 Non-GAAP EPS of $1.21 beats by $0.12 .
- Revenue of $942M (-6.7% Y/Y) beats by $19.05M .
- “2022 marked another impressive year for Horizon, with double-digit net sales growth across our commercial portfolio and significant progress executing on our strategy to maximize the value of our growth medicines, expand our global presence and advance our pipeline, including generating positive topline results from our Phase 2 trial in Sjögren’s syndrome across both patient populations,” said Tim Walbert, chairman, president and chief executive officer, Horizon.
For further details see:
Horizon Therapeutics Non-GAAP EPS of $1.21 beats by $0.12, revenue of $942M beats by $19.05M